Table of Contents
| << Previous Issue | Nov 2012 (Vol: 2012, Issue: 11) | Next Issue >> |
- Section: Licensing
-
Ardelyx Licenses NHE3 Inhibitor Programme to AstraZeneca in its First Major Deal
-
Bayer Spin-Off AiCuris Licenses Phase III-Ready Antiviral to Merck & Co.
-
Alnylam Partners with Sanofi’s Genzyme to Advance its ALN-TTR Programme in Asia-Pacific
-
Ironwood Pharmaceuticals Chooses AstraZeneca as Chinese Partner for Linaclotide
- Section: Mergers & Acquisitions
-
Cinven Makes Second Speciality Pharma Acquisition of 2012
-
BioCryst and Presidio Merge to Compete in Oral Hepatitis C Drug Development
-
Pfizer Forays into ADHD Market by Exercising Option to Acquire NextWave Pharmaceuticals
-
Takeda Bolsters its CNS Pipeline with Envoy Therapeutics Purchase
-
India’s Sun Pharma Targets US Dermatology Market with Dusa Pharmaceuticals Acquisition
-
Pernix Therapeutics Expands Generic and Branded Product Portfolios with Cypress Pharmaceutical Acquisition
-
Allergan Boosts Facial Aesthetics Business with SkinMedica Purchase
- Section: Research & Development
-
Menarini Forms Antibody-Based Drug Alliance with Oxford BioTherapeutics
-
Ensemble Therapeutics Collaborates with Boehringer Ingelheim on Macrocyclic Drug Discovery
-
Vertex Partners with GSK and Janssen on Phase II Studies of All-Oral HCV Treatment Regimens
RSS